| 标题 |
A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD
一项III期、随机、双盲、平行组、事件驱动的心血管安全性研究，在已确定患有心血管疾病（CVD）或慢性肾脏疾病和/或至少两种体重相关并发症或CVD危险因素的超重或肥胖受试者中，皮下注射BI 456906与安慰剂进行比较
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Brief Summary This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet. The purpose of this study is to find out whether people with overweight or obesity who take a medicine called survodutide (BI 456906) are less or more likely to develop serious cardiovascular problems. It also aims to find out whether health parameters like blood pressure improve. Overweight and obesity are linked to cardiovascular disease. Survodutide is a medicine that is developed to help people with obesity or overweight to lose weight. |
| 求助人 | |
| 下载 | 暂无链接，等待应助者上传 |
PDF的下载单位、IP信息已删除
小白
荟萃分析
Wells
从容芮
GingerF
Alex
Virtual
PiX0
MchemG
酷酷的一笑
yjy
ly152837
klpkyx
Lees
涂生
风清扬
大模型
柴桑青木
mmyhn
Jasper
皖公网安备34019202002308
